Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

Irie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S · Endocrine Journal

The first human NMN administration study. No clinical symptoms or vital-sign changes at any dose; downstream nicotinamide metabolites rose dose-dependently, establishing that oral NMN is absorbed and metabolised in people.

Population

Healthy Japanese men

Intervention

Single oral doses of 100, 250 and 500 mg NMN, each followed for 5 hours

Comparator

None — single-arm dose escalation

Limitations

Ten men, single doses, no control arm, five hours of follow-up. Safety in the narrowest sense; NAD+ itself was not the endpoint.